Skip to main content
. Author manuscript; available in PMC: 2023 Nov 24.
Published in final edited form as: J Hepatol. 2021 Apr 12;75(2):424–434. doi: 10.1016/j.jhep.2021.03.013

Fig. 2. The early time-point miRNA-based model.

Fig. 2.

(A) miRNA included within the model. (B) Model performance (n = 182; AUC 0.78 [95% CI 0.71–0.84; p <0.0001*]; pseudo r2 = 0.2213; HL statistic 12.67 [p = 0.12]). (C) MetaCore™ pathway analysis including all miRNA within the model. (D) MetaCore™ pathway analysis including miRNA within both time-point models (miR-149 and −191) (E) MetaCore™ pathway analysis including miRNA only within the early time-point model (miR-20a, −27a, −150). (E) Comparisons with other outcome prediction models with and without threshold values using the DeLong method. Statistical significance set as per Benjamini-Hochberg procedure with a false discovery rate of 0.05 (*p <0.026). ALFSGPI, Acute Liver Failure Study Group prognostic index; HL, Hosmer-Lemeshow; KCC, King’s College criteria; MELD, model for end-stage liver disease; miR/miRNA, microRNA; OR, odds ratio.